Anoctamin 7 (ANO7)

Anoctamin 7 (ANO7) is a prostate-specific, polytopic membrane protein with calcium-dependent phospholipid scramblase activity, involved in the regulation of vesicle formation, exosome trafficking, and possibly cell-cell adhesion in prostate tissue. It is considered a biomarker and experimental therapeutic target in prostate cancer, where its elevated expression correlates with poor clinical outcomes. ANO7 is part of the anoctamin family of transmembrane proteins, many of which act as ion channels, but ANO7 itself is proposed to lack significant chloride channel activity and instead acts as a membrane scramblase. The gene is subject to alternative splicing, resulting in multiple isoforms, with the long isoform (ANO7L) primarily localizing to the plasma membrane. There is no evidence for a distinct "ANO7L1" entity in current scientific databases or literature.

Other names

NGEPTMEM16GAnoctamin-7ANO7L (long isoform)NGEP-LNGEP-S

Antibody-based targeting for immunotherapy (experimental, based on cell surface localization in prostate cancer); mechanisms for direct small molecule modulation are not established